Item no. |
HY-12403A-10mM |
Manufacturer |
MedChem Express
|
CASRN |
2855063-75-9 |
Amount |
10mM/1mL |
Quantity options |
10mM/1mL
10 mg
25 mg
50 mg
5 mg
|
Category |
|
Type |
Peptides |
Specific against |
other |
Purity |
99.87 |
Formula |
C43H66N12O13 |
Citations |
[1]Gómez-Mendoza DP, et al. Angiotensin-(1-7) oral treatment after experimental myocardial infarction leads to downregulation of CXCR4. J Proteomics. 2019;208:103486.<br/>[2]Li P, et al. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997 Jan;29(1 Pt 2):394-400.<br/>[3]Khajah MA, et al. Anti-Inflammatory Action of Angiotensin 1-7 in Experimental Colitis. PLoS One. 2016 Mar 10;11(3):e0150861.<br/>[4]Alzayadneh EM, et al. Angiotensin-(1-7) abolishes AGE-induced cellular hypertrophy and myofibroblast transformation via inhibition of ERK1/2. Cell Signal. 2014 Sep 19. pii: S0898-6568(14)00314-3.<br/>[5]Janatpour ZC, et al. Subcutaneous Administration of Angiotensin-(1-7) Improves Recovery after Traumatic Brain Injury in Mice. J Neurotrauma. 2019;36(22):3115-3131. |
Smiles |
O=C([C@H](CC1=CNC=N1)NC([C@@]([H])(NC([C@H](CC2=CC=C(C=C2)O)NC([C@@H](NC([C@@H](NC([C@H](CC(O)=O)N)=O)CCCNC(N)=N)=O)C(C)C)=O)=O)[C@H](CC)C)=O)N3CCC[C@H]3C(O)=O.CC(O)=O |
ECLASS 10.1 |
32160409 |
ECLASS 11.0 |
32160409 |
UNSPSC |
12352202 |
Alias |
TXA127 (acetate); Angiotensin (1-7) (acetate); Ang-(1-7) (acetate) |
Available |
|
Product Description |
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium[1][2][3]. |
StorageTemperature |
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture) |
Shipping |
Blue Ice |
Manufacturers Applications |
COVID-19-anti-virus |
MolecularWeight |
959.06 |
Clinical Information |
Phase 3 |
Manufacturers Research Area |
Endocrinology; Inflammation/Immunology; Cardiovascular Disease |
Solubility |
H2O : 62.5 mg/mL (ultrasonic) |
Target |
Angiotensin Receptor; Angiotensin-converting Enzyme (ACE); Endogenous Metabolite |
Manufacturers Target |
Angiotensin Receptor; Angiotensin-converting Enzyme (ACE); Endogenous Metabolite |
Isoform |
AT1 Receptor |
Manufacturers Pathway |
GPCR/G Protein; Metabolic Enzyme/Protease |
Manufacturers Product type |
Peptides |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.